PD-L1在妇科癌症患者中新兴且具有挑战性的作用:结合临床病理学考量的更新综述
本文综述PD-L1在妇科恶性肿瘤中的表达及其免疫检查点抑制剂治疗中的意义。PD-L1表达随肿瘤分期和分子亚型差异极大,临床试验常用SP142、28-8、22C3和SP263检测。文章为各类妇科癌症的PD-L1病理评估与报告提供指导。
要点
- PD-L1是表达于T淋巴细胞、B淋巴细胞和抗原呈递细胞的1型跨膜蛋白配体,为癌症免疫调节的关键抑制性检查点。
- 妇科恶性肿瘤PD-L1免疫组化表达随肿瘤分期和分子亚型差异极大。
- 临床试验最常用PD-L1检测为SP142、28-8、22C3和SP263,各已在特定平台严格验证。
核心结论
- PD-L1在妇科癌症中的表达高度可变,需结合肿瘤分期、分子亚型及错配修复状态、肿瘤突变负荷等因素进行病理评估与报告。
研究设计与样本
- 本文为叙述性综述,广泛回顾PD-L1在不同类型妇科癌症中的表达,并为病理评估和报告提供指导。
主要发现
- PD-L1免疫组化表达在妇科恶性肿瘤中随肿瘤分期和分子亚型差异极大。
- 妇科癌症免疫治疗反应不一,受遗传和蛋白表达谱影响,包括错配修复状态、肿瘤突变负荷和检查点配体表达。
- 临床试验中最常用的PD-L1检测为SP142、28-8、22C3和SP263,各已在特定平台严格验证。
关键数值与推荐
- 临床实践中识别免疫检查点抑制剂治疗合适候选者的标准方法为对肿瘤组织进行PD-L1免疫组化评估。
- 临床试验最常用PD-L1检测为SP142、28-8、22C3和SP263。
临床怎么用
- 临床实践中采用免疫组化评估肿瘤组织PD-L1表达以筛选免疫检查点抑制剂治疗候选者。
- 病理评估和报告应结合肿瘤分期、分子亚型、错配修复状态、肿瘤突变负荷和检查点配体表达等因素。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over recent years, there has been significant progress in the development of immunotherapeutic molecules designed to block the PD-1/PD-L1 axis. These molecules have demonstrated their ability to enhance the immune response by prompting T cells to identify and suppress neoplastic cells. PD-L1 is a type 1 transmembrane protein ligand expressed on T lymphocytes, B lymphocytes, and antigen-presenting cells and is considered a key inhibitory checkpoint involved in cancer immune regulation. PD-L1 immunohistochemical expression in gynecological malignancies is extremely variable based on tumor stage and molecular subtypes. As a result, a class of monoclonal antibodies targeting the PD-1 receptor and PD-L1, known as immune checkpoint inhibitors, has found successful application in clinical settings. In clinical practice, the standard method for identifying suitable candidates for immune checkpoint inhibitor therapy involves immunohistochemical assessment of PD-L1 expression in neoplastic tissues. The most commonly used PD-L1 assays in clinical trials are SP142, 28-8, 22C3, and SP263, each of which has been rigorously validated on specific platforms. Gynecologic cancers encompass a wide spectrum of malignancies originating from the ovaries, uterus, cervix, and vulva. These neoplasms have shown variable response to immunotherapy which appears to be influenced by genetic and protein expression profiles, including factors such as mismatch repair status, tumor mutational burden, and checkpoint ligand expression. In the present paper, an extensive review of PD-L1 expression in various gynecologic cancer types is discussed, providing a guide for their pathological assessment and reporting.
引用
- Santoro A, Angelico G, Inzani F, et al. The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations. Gynecol Oncol. 2024. PMID: 38295614. doi:10.1016/j.ygyno.2024.01.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。